Holen Sie sich die Stockscreener-App
78.37
4.19%
3.19
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Livforsakringsbolaget Skandia Omsesidigt Has $1.44 Million Stake in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Incorporated $CORT Stock Holdings Increased by Voya Investment Management LLC - MarketBeat
Aug PostEarnings: Should I average down on CNOB stockEarnings Trend Report & Real-Time Chart Breakout Alerts - خودرو بانک
Gap Down: Is Topgolf Callaway Brands Corp. stock a good pick for beginners2025 Technical Patterns & AI Forecasted Entry and Exit Points - خودرو بانک
13,400 Shares in Corcept Therapeutics Incorporated $CORT Bought by Strs Ohio - MarketBeat
Alliancebernstein L.P. Lowers Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Support Test: What is the next catalyst for QTRX2025 Market Outlook & Free Technical Pattern Based Buy Signals - خودرو بانک
Iron Gate Global Advisors LLC Buys Shares of 3,500 Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Incorporated $CORT Stock Holdings Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
Market Outlook: What is the next catalyst for FIZZMarket Performance Report & Consistent Growth Equity Picks - خودرو بانک
Corcept Therapeutics Incorporated $CORT Shares Bought by Jones Financial Companies Lllp - MarketBeat
Corcept’s (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint - MSN
Buyback Watch: Can Corcept Therapeutics Incorporated weather a recession2025 Short Interest & Weekly Breakout Stock Alerts - خودرو بانک
Corcept Therapeutics Incorporated $CORT Stake Lowered by Parallel Advisors LLC - MarketBeat
United Services Automobile Association Acquires Shares of 6,069 Corcept Therapeutics Incorporated $CORT - MarketBeat
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance
Corcept (CORT): Buy, Sell, or Hold Post Q2 Earnings? - FinancialContent
Intech Investment Management LLC Purchases 14,628 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Can't Escape Teva's Mifepristone Antitrust Suit - Law360
Corcept Fails to Escape Antitrust Claims in Drug Kickback Case - Bloomberg Law News
Drugmaker Corcept must face Teva lawsuit over mifepristone 'monopoly' for rare disorder - Reuters
Empowered Funds LLC Purchases 81,297 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Price Target Raised to $140.00 at Canaccord Genuity Group - MarketBeat
Bayforest Capital Ltd Has $811,000 Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Acadian Asset Management LLC Boosts Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Coppell Advisory Solutions LLC Buys 14,590 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
AQR Capital Management LLC Sells 23,561 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Scientech Research LLC Has $1.62 Million Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Price Target at $134.50 - MarketBeat
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer - sharewise.com
FDA Accepts NDA for Relacorilant in Platinum-Resistant Ovarian Cancer - Targeted Oncology
Central serous chorioretinopathy Pipeline Analysis & Clinical - openPR.com
Central serous chorioretinopathy Pipeline Analysis & Clinical Trials, 2025, DelveInsight | Targeted Therapy Technologies, Corcept Therapeutics, Bayer, and others - Barchart.com
Jacobs Levy Equity Management Inc. Decreases Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
FDA accepts Corcept’s new drug application for ovarian cancer treatment - Investing.com
Corcept's ovarian cancer treatment under FDA review (CORT) - Seeking Alpha
Corcept Therapeutics Says FDA Accepts NDA on Relacorilant for Treating Ovarian Cancer - MarketScreener
Fda reviews Corcept's nda for relacorilant in drug-resistant ovarian cancer - MarketScreener
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Checkpoint Capital L.P. Acquires Shares of 5,000 Corcept Therapeutics Incorporated $CORT - MarketBeat
Published on: 2025-09-08 19:18:57 - beatles.ru
Birchview Capital LP Decreases Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
0.03%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):